esketamine has been researched along with 2019 Novel Coronavirus Disease in 3 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 3 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bansbach, J; Heinrich, S; Kalbhenn, J; Kaufmann, K; Wenz, J | 1 |
| Baldin, P; Declerfayt, C; Gerard, L; Hantson, P; Henrie, J; Laterre, PF; Lejeune, A; Robert, A | 1 |
| Elowe, J; Khazaal, Y; Kloucek, P; Preisig, M; Ros, T; Tadri, M; Vandeleur, C; Vandenberghe, F; Verloo, H; Von Guntenb, A | 1 |
1 review(s) available for esketamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
[Psychiatry].
Topics: COVID-19; Depressive Disorder, Treatment-Resistant; Humans; Ketamine; Neurofeedback; Pandemics; Psychiatry; Telemedicine | 2021 |
2 other study(ies) available for esketamine and 2019 Novel Coronavirus Disease
| Article | Year |
|---|---|
Sevoflurane in combination with esketamine is an effective sedation regimen in COVID-19 patients enabling assisted spontaneous breathing even during prone positioning.
Topics: Cohort Studies; COVID-19; Humans; Ketamine; Prone Position; Respiration, Artificial; Sevoflurane | 2022 |
Profile of liver cholestatic biomarkers following prolonged ketamine administration in patients with COVID-19.
Topics: COVID-19; Humans; Ketamine; Liver; Retrospective Studies | 2023 |